Introduction
Renal cell carcinoma (RCC) is the most frequent type of primary renal neoplasms, accounting for ~90% of cases. 1 Various histologic subtypes of RCC have been described, of which clear cell RCC (ccRCC) is the major subtype. 2 Metastasis is seen in 20%-30% of RCC patients during diagnosis. 3 With the improvement in diagnostic and therapeutic techniques, the 5-year survival rate of RCC has increased to ~55%. Unfortunately, metastatic RCC has a 5-year survival rate of only ~10%. 4 The mechanism underlying the development and progression of RCC is far from being completely understood. Thus, there is a strong necessity to identify potential diagnostic markers and pathways or proteins actively engaged in RCC carcinogenesis.
Serine/threonine kinase 39 (STK39, also known as SPAK/PASK/STE20-SPS1 homolog) belongs to the Ste20-like kinase family. It contains an N-terminal proline and alanine repeats (PAPA box), a serine/threonine kinase catalytic domain, a putative nuclear localization signal, and a C-terminal region. 5 STK39 interacts with oxidative stress response 1 and several cation chloride cotransporters, KCC3, 
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Zhao et al NKCC1, and NKCC2, thus regulating fluid/ion homeostasis. 6 STK39, as a Ser/Thr kinase, is able to activate the mitogenactivated protein kinase p38 signaling pathway, suggesting its involvement in stress responses. 5 Recently, increasing evidence has accumulated supporting the roles of STK39 in human diseases. Genetic variants of STK39 are associated with autism, 7 hypertension, [8] [9] [10] [11] and Parkinson's disease. 12, 13 Reduced expression of STK39 is correlated with prostate cancer metastasis, 14 as well as treatment resistance of breast cancer. 15 STK39 is being silenced in B-cell lymphoma and STK39 knockdown protects B cells from DNA double-strand breaks-induced apoptosis through c-Jun NH2-terminal kinase (JNK). 16 On the contrary, STK39 expression correlated significantly with the prognosis of non-small-cell-type lung cancer (NSCLC). 17 Nevertheless, no reports have described the expression and functions of STK39 in RCC.
In the current study, we analyzed the mRNA and protein expression of STK39 in RCC and paired adjacent normal renal tissues in a cohort of 25 patients. The functions of STK39 on cell proliferation and apoptosis were also investigated. Our results indicated that STK39 may exert antiapoptotic function in RCC.
Materials and methods

Patients and tissue samples
Ethical approval (B2016-161R) was provided by the Ethics Committee of Zhongshan Hospital (Shanghai, China). Twenty-five patients (14 males and 11 females) with RCC were chosen from Zhongshan Hospital between 2011 and 2013. Written informed consent was collected from all the enrolled patients in accordance to the guidelines of the Ethics Committee. The average age of these patients was 59±9 years. The study cohort consisted of 13 patients at stage I and 12 patients at stage II. During surgical procedures, RCC samples and matched adjacent normal renal samples were collected, fresh-frozen, and stored in −80°C. rna isolation, reverse transcription, and real-time polymerase chain reaction (Pcr)
Total RNA was isolated with Trizol reagent according to the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). Following treatment with DNase to avoid DNA contamination, NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Rockford, IL, USA) was used to determine the concentrations of RNA samples. Two microgram of total RNA was reverse transcribed by the two-step RT-PCR system (Thermo Fisher Scientific). Subsequently, real-time PCR was performed on an ABI 7300 instrument (Applied Biosystems, Foster City, CA, USA) with the complementary DNA as template by using SYBR Green PCR kit (Thermo Fisher Scientific). The primers for STK39 were 5′-TGCCAGACCAGTATGGATGAA-3′ (forward) and 5′-GGTGTAATAGGTCACTACGTTGG-3′ (reverse), and primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 5′-CTGGGCTACACTGAGCACC-3′ (forward) and 5′-AAGTGGTCGTTGAGGGCAATG-3′ (reverse). Each sample was run in triplicate. STK39 expression normalized with the internal control GAPDH was calculated using the 2 −∆∆CT method as previously described.
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Protein extraction and Western blotting 
Bioinformatics analysis
A microarray dataset of 72 ccRCC samples and paired non-tumorous samples was downloaded from NCBI Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/ geo/). The STK39 expression between the RCC samples and normal samples was compared by Student's t-test.
To elucidate the possible processes and pathways associated with STK39 expression, Gene set enrichment analysis (GSEA) was performed on the Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga/) RCC OncoTargets and Therapy 2018:11 submit your manuscript | www.dovepress.com
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sTK39 and renal cell carcinoma cohort using the GSEA software version 2.0 as previously described. 17 cell culture and treatment ACHN, 786-0, and HK-2 cells were purchased from the Shanghai Institute of Cell Biology (Shanghai, China). Cells were grown in Dulbecco's Modified Eagle's Medium (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA) and penicillin/ streptomycin at 37°C with 5% CO 2 .
siRNA oligonucleotides targeting STK39 (STK39 siRNA) or scrambled control siRNA (Control siRNA) were ordered from Genepharm Technologies (Shanghai, China). siRNA at a concentration of 120 nM was transfected into ACHN and 786-0 cells using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. After 48 h, the knockdown efficiency was determined by real-time PCR and Western blotting.
Full-length STK39 cells were cloned into the expression vector pCDNA3.1 (Invitrogen). ACHN cells were transfected with control vector or expression plasmid encoding STK39 and treated with either dimethyl sulfoxide (DMSO) or 10 μM p38 inhibitor, SB203580 (Merck, Darmstadt, Germany). After 48 h, protein samples were extracted and subjected to Western blotting.
cell proliferation analysis
Cell counting kit-8 (CCK-8; Beyotime) assays were conducted to detect cell proliferation according to the manufacturer's protocols. In brief, ACHN and 786-0 cells were seeded in 96-well plates. Following culture overnight, the cells were transfected with STK39 siRNA or control siRNA. After incubation for indicated time periods, CCK-8 solution was dispensed to every well. Following culture for 1 h, optical density at a wavelength of 450 nm (OD 450) was determined with a Model 550 microplate reader (BioRad, Richmond, CA, USA).
apoptosis analysis ACHN and 786-0 cells were plated in 6-well plates at a density of 3×10 5 per well. After culturing overnight to allow cell adherence, transfection of STK39 siRNA or control siRNA was carried out as described earlier. At 48 h posttransfection, cell apoptosis was measured by labeling with Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) (eBioscience, San Diego, CA, USA) followed by fluorescence-activated cell sorting (FACScalibur; BD Biosciences, Franklin Lakes, NJ, USA). The percentages of apoptotic cells (lower right quadrant) were estimated from three independent experiments.
statistical analysis
All experiments were performed three times. Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA). Comparisons between two groups and among more than two groups were performed using Student's t-test and one-way ANOVA followed by Tukey's post-test, respectively. A P-value less than 0.05 was considered as statistically significant.
Results
expression of sTK39 is elevated in rcc tissues
To determine whether STK39 expression is upregulated in RCC, 25 pairs of RCC tissues and adjacent non-tumorous normal renal tissues were collected and STK39 mRNA expression was evaluated by real-time PCR. The results showed that STK39 mRNA levels were significantly greater in RCC tissues than in adjacent normal tissues ( Figure 1A , P,0.0001). Furthermore, a microarray dataset (accession number: GSE53757) of 72 ccRCC samples and paired nontumorous sample was downloaded from the NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/). The public available dataset also showed that the expression of STK39 mRNA was increased in human RCC tissues ( Figure 1B, P,0.001) . We then performed Western blotting to detect STK39 protein expression in 8 paired RCC and normal tissues. The results indicated that STK39 expression was significantly elevated in tumor tissues at translation level ( Figure 1C , P,0.05).
silencing of sTK39 by rna interference (rnai)
Real-time PCR and Western blot analyses were performed to evaluate the mRNA and protein expression of STK39 in two RCC cell lines, ACHN and 786-0, and human renal proximal tubule cell line, HK-2, respectively (Figure 2A ). The expression of STK39 was significantly higher in both RCC cell lines than in HK-2 cells.
To study the functions of STK39 in RCC cells, firstly, we used a specific siRNA against STK39 to knockdown the expression of STK39 in ACHN and 786-0 cells. Using realtime PCR and Western blotting, we confirmed the successful knockdown of STK39 in both cell lines with a knockdown efficiency of about 85% ( Figure 2B and C). Transfection with control siRNA had no effects on the expression of STK39 as compared to cells without any treatment (wild-type, WT).
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Zhao et al sTK39 knockdown inhibits rcc cell proliferation CCK-8 assays were then performed to assess the changes to RCC cell proliferation following STK39 knockdown. As demonstrated in Figure 3 , the proliferation of ACHN and 786-0 cells was significantly reduced in STK39 siRNAtransfected cells compared with relevant WT and control siRNA-transfected cells. These findings suggested that downregulation of STK39 expression inhibited RCC cell proliferation in vitro.
sTK39 knockdown induces rcc cell apoptosis
We evaluated RCC cell apoptosis after STK39 knockdown by Annexin V-FITC/PI staining and flow cytometry analysis. As shown in Figure 4A and B, knockdown of STK39 in ACHN and 786-0 cells caused a significant increase in the rate of cell apoptosis as compared with cells transfected with control siRNA or without any treatment (WT).
sTK39 knockdown affects the expression of Pcna, Bcl-2, and Bax
In addition, we compared the expression level of proliferation marker, PCNA, 19 and apoptosis-regulating proteins, Bcl-2 and Bax, 20 by Western blotting. We found that PCNA and the anti-apoptosis protein Bcl-2 were reduced in STK39 siRNA-transfected RCC cells compared to WT and control siRNA-transfected cells, while the apoptosis-promoting protein Bax was increased ( Figure 5 ). These findings confirmed the results of CCK-8 and flow cytometry.
sTK39 is positively correlated with p53 and p38 pathways Next, we tried to elucidate the pathways that are modulated by STK39 during renal carcinogenesis. By GSEA on RCC cohort from TCGA, we found that genes of p53 and p38 pathways were strongly associated with high expression of STK39 ( Figure 6A) .
To validate the results of GSEA, the levels of p53, p38, phosphorylated p38 (p-p38), and c-Myc were determined by Western blotting (Figure 6B and C). p-p38 and c-Myc were significantly decreased, and p53 was increased after STK39 expression was suppressed compared with the relevant control cells. The levels of p38 remained unchanged after STK39 siRNA transfection.
In order to clarify the involvement of p38 signaling, ACHN cells with STK39 overexpression were exposed to p38 inhibitor (SB203580). The expression of p53 and C-Myc, as well as the phosphorylation of p38, was detected ( Figure 6D ). STK39 overexpression significantly elevated the levels of C-myc and p-p38, but reduced p53 expression. Such effects were weakened by SB203580 treatment. These findings suggested the regulatory effects of STK39 on p38, p53, and c-Myc. Consistently, the effects of SB203580 treatment that suppressed cell proliferation ( Figure 6E ) and increased cell apoptosis ( Figure 6F ) were significantly attenuated by STK39 overexpression. These findings suggested that p38 signaling was involved in the oncogenic function of STK39 in RCC cells.
Discussion
Previous studies showed that STK39 is aberrantly expressed in several types of tumors [14] [15] [16] [17] and its functions in cancer are also analyzed. Hendriksen et al reported that primary prostate cancer patients with lower mRNA levels of STK39 had a higher incidence of metastases following radical prostatectomy.
14 In another study, Cleator et al revealed that reduced STK39 expression was correlated with treatment resistance of breast cancer by expression microarray analysis. 15 Balatoni et al observed a reduced expression of STK39 in B-cell lymphoma, and they found that STK39 knockdown in B cells suppressed DNA double-strand breaksinduced apoptosis through JNK. 16 However, contradictory roles for STK39 have been reported in NSCLC. Li et al found that STK39 expression is upregulated in NSCLC and that knocking down of STK39 expression reduced lung cancer cell proliferation, migration, and invasion. 17 These studies indicate the complicated functions of STK39 in different 
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Zhao et al types of cancers. The present study was the first to show the increased expression of STK39 in RCC tissues at both transcriptional and translational levels, suggesting the potential involvement of STK39 in RCC development.
The present study also investigated the functions of STK39 on RCC cell proliferation and apoptosis in vitro. Knocking down of STK39 expression in two RCC cell lines significantly inhibited cell proliferation and induced cell apoptosis, which was in line with the previous findings in NSCLC. 17 PCNA is a prognostic marker for RCC. 21 Anti-apoptotic effect of Bcl-2 and pro-apoptotic effect of Bax have been widely studied in various cell types. 20 Here, STK39 silencing caused a decrease in the protein expression of PCNA and Bcl-2, and an increase in that of Bax, confirming the biological functions of STK39 on cell proliferation and apoptosis. p53 and p38 signaling pathways, which play crucial roles in the regulation of cell proliferation, transformation, and apoptosis, are important during carcinogenesis. 19, 22 p38 has been reported to activate p53 in response to ultraviolet radiation. 23 C-Myc, a downstream transcription factor of p38, 24 acts as an oncogene during renal carcinogenesis. 25 Previous studies have demonstrated that STK39 is able to activate the p38 signaling pathway. 5, 17 The current study identified that STK39 regulated the p53 and p38 signaling pathways by GSEA analysis. This finding was validated
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Conclusion
In summary, the data presented here suggest that STK39 is overexpressed in RCC tissues. STK39 knockdown in RCC cells inhibits cell proliferation by inducing cell apoptosis via regulating p38 signaling pathway. Thus, STK39 may be a diagnostic biomarker and treatment target for RCC.
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